Search results
Results from the WOW.Com Content Network
Helen Reddel or Helen Kathryn Reddel is a respiratory physician, a professor at Macquarie University, and adjunct professor at the University of Sydney, Chair of the Global Initiative for Asthma, [1] [2] who was awarded an Order of Australia in 2024, for services to respiratory medicine. [3]
ASCIA was formed in 1991 by the merging of the Australian College of Allergy with the Australasian Society of Immunology Clinical Immunology Group. [ 1 ] ASCIA publishes guidelines and position statements on the management of allergy and other immune diseases, provides online training courses, online educational resources, hosts the ASCIA ...
The Buteyko method emphasizes the role of carbon dioxide and hyperventilation in respiratory diseases as well as overall health. It is known that hyperventilation can lead to low carbon dioxide levels in the blood (or hypocapnea), which can subsequently lead to disturbances of the acid-base balance in the blood and lower tissue oxygen levels.
Australian Medicines Handbook (AMH) is a peer-reviewed medicines prescribing guide for Australian health professionals. The handbook is available in paper and digital formats and is supplemented by the AMH Aged Care Companion and the AMH Children's Dosing Companion. It is included in the Clinical Information Access Portal.
GINA conducts continuous review of scientific publications on asthma and is a leader in disseminating information about the care of patients with asthma. [2] GINA publishes resources such as evidence-based guidelines for asthma management, and runs special events such as World Asthma Day. GINA's guidelines, revised each year, are used by ...
Sensitizer-induced occupational asthma is an immunologic form of asthma which occurs due to inhalation of specific substances (i.e., high-molecular-weight proteins from plants and animal origins, or low-molecular-weight agents that include chemicals, metals and wood dusts) and occurs after a latency period of several weeks to years. [1]
Asthma phenotyping and endotyping has emerged as a novel approach to asthma classification inspired by precision medicine which separates the clinical presentations of asthma, or asthma phenotypes, from their underlying causes, or asthma endotypes. The best-supported endotypic distinction is the type 2-high/type 2-low distinction.
The proposed mechanism is that while LABAs relieve asthma symptoms, they can also promote bronchial inflammation and sensitivity without warning. [23] On February 18, 2011, the FDA issued a safety alert for long-acting β agonists. [24]